JY306 NK cell therapy for relapsed blood cancer with CD70 marker
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational immune cell treatment (JY306 NK cells) for adults whose blood cancer has come back or not responded to standard therapy, and whose cancer cells have a high amount of a specific marker called CD70. The goal is to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer that is relapsed or refractory (came back or didn't respond to treatment).
- Your cancer cells must have high levels of the CD70 marker (more than 80% positive on testing).
- You are between 18 and 75 years old.
- You are in generally good health, with a performance score (KPS) of 80 or higher, meaning you can care for yourself and do most daily activities.
- Your heart, lungs, kidneys, and liver function meet specific safety levels (checked by tests).
- You cannot be pregnant or planning pregnancy during and for a period after treatment, and you must agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
This trial tests a new treatment, JY231, for people whose B-cell lymphoma has returned or stopped responding to previous therapies. It aims to see if JY231 can help shrink tumors or control the disease.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial tests a new treatment made from your own immune cells (NK cells) that are modified to recognize and attack cancer cells with a marker called CD7. It is for people whose blood cancer has returned or not improved with other treatments.
This trial tests an off-the-shelf natural killer (NK) cell treatment for children whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or hasn't responded to standard therapy. The NK cells are designed to target and kill leukemia cells without needing to be a match for your child.
Hear when a new Relapsed or Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.